Digest Network How does it work
Network
/
Society
Ge
Not verified

Genmab A/S

What we write about

BiotechnologyHealthMedicine - variousOncologyPharmaceuticals

36 Press releases

View all press releases
05/10/2026
Industria
Scienza
Biotechnology
Pharmaceuticals
Oncology
Sanità
Health
Medicine - various
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Source
Genmab A/S
Issuer
Business Wire
1.00
0
03/10/2026
Industria
Oncology
Health
Sanità
Medicine - various
Pharmaceuticals
Biotechnology
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Source
Genmab A/S
Issuer
Business Wire
1.00
0
06/07/2026
Oncology
Health
Medicine - various
Sanità
Pharmaceuticals
Biotechnology
Industria
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Source
Genmab A/S
Issuer
Business Wire
1.00
0
29/06/2026
Cardiology
Third age
Biotechnology
Pharmaceuticals
Oncology
Health
Windows / Shopping
Medicine - various
Eventi
Industria
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Source
Genmab A/S
Issuer
Business Wire
1.00
0
13/06/2026
Cardiology
Third age
Biotechnology
Pharmaceuticals
Oncology
Health
Windows / Shopping
Medicine - various
Eventi
Industria
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Source
Genmab A/S
Issuer
Business Wire
1.00
0
21/05/2026
Oncology
Health
Medicine - various
Sanità
Pharmaceuticals
Biotechnology
Eventi
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Source
Genmab A/S
Issuer
Business Wire
1.00
0
13/04/2026
Industria
Oncology
Health
Medicine - various
Sanità
Pharmaceuticals
Biotechnology
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Source
Genmab A/S
Issuer
Business Wire
1.00
0
16/01/2026
Oncology
Food hygiene
Health
Medicine - various
Pharmaceuticals
Biotechnology
Industria
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Source
Genmab A/S
Issuer
Business Wire
1.00
0
07/01/2026
Scienza
Sanità
Pharmaceuticals
Oncology
Tecnica
Medicine - various
Biotechnology
Various technologies
Health
Labour market
Industria
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
Source
Genmab A/S
Issuer
Business Wire
1.00
0
29/12/2026
Biotechnology
Sanità
Health
Medicine - various
Genmab Portfolio Prioritization Update
Source
Genmab A/S
Issuer
Business Wire
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0